← Search & browse all drugs
MUSCULO-SKELETAL SYSTEM › DRUGS FOR TREATMENT OF BONE DISEASES › DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION › Other drugs affecting bone structure and mineralization
strontium ranelate
M05BX03
Forms & Strengths
- Powder for oral suspension: 2g sachet
- Tablets: 2g
Adult Dosing
- 2g daily, preferably at bedtime
- Dose adjustments not necessary for renal impairment
- Not recommended for patients with severe renal impairment
Pediatric Dosing
- Not recommended for patients under 18 years old
Indications
- Treatment of osteoporosis to reduce vertebral and hip fracture risk
- Treatment of osteoporosis in postmenopausal women and men
Mechanism of Action
- Dual action: increases bone formation and decreases bone resorption
- Increases osteoblast activity and decreases osteoclast activity
Contraindications
- Hypersensitivity to strontium ranelate or any excipients
- Pregnancy and breastfeeding
- Severe renal impairment (creatinine clearance below 30ml/min)
Adverse Reactions
- Common: nausea, diarrhea, headache, dermatitis
- Uncommon: venous thromboembolism, allergic reactions, seizures
Drug Interactions
- Avoid administration with calcium or aluminium-containing products
- Increased risk of venous thromboembolism with estrogens
- Monitor digoxin levels when co-administering
Curated Content: Needs Vetting Before Put to Clinical Use